Mediolanum Farmaceutici

Biomedica Foscama Industria Chimico-farmaceutica

Consiglio Nazionale Delle Ricerche

Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Euticals Spa

Alfa Farmaceutici S.p.a.

Laboratorio Farmaceutico C.t. S.r.l.

Angelini Ricerche S.p.a. Societa'consortile

Mediolanum Farmaceutici S.r.l. Consiglio Nazionale Delle Ricerch

Instituto Chimico Internazionale Dr. Giuseppe Rende S.r.l.

Istituto Chimico Internazionale Dr. Giuseppe Rende S.r.l.

Mario Brufani

Stefano Maiorana

Pier G Pagella

Stefano Ceccarelli

Romolo Scuri

Enrico Ferrari

Agnese Paesano

Patrizia Giannetti

Sperandina Lappa

Maria C Cesta

Donata Marchesini

Massimo Pomponi

Luigi Filocamo

Mario Pinza

Maria Alessandra Alisi

Flaminia Pavone

Sergio Zanarella

Giorgio Rende

Alberto Oliverio

Maurizio Marta

Gianluca Gostoli

Nicola Cazzolla

Egidio Marchi

Barbara Garofalo

Giuseppe Mascellani

Patrizia Terni

Pier L Rugarli

Antonella Loche

Donato Pocar

Rinaldo Marini Bettolo

Claudio Milanese

Adriana Caterina Maggi

Vincenzo Perlini

Luisa Maria Migneco

Alessandra Alisi

Paolo Maria Farina

Zanarella Sergio

Simonetta Antonaroli

Armandodariano Bianco

Giuseppe Lo Baido

Patrizia De Vellis

Sergio Zanarcella

Lo B Giuseppe

Bianco Armandodariano

Antonaroli Simonetta

Gillian Ashcroft

Marilena Giannangeli

Carlo Meroni

Francesca Ceccacci

Claudio Castelland

Luigi Eieocamo

Patrizia DeVellis

Riccardo Bernardi

Giacomina Mandelli

Lucia Mairani

Roberta Joudioux

Pierfranco Bellomo

Claudio Castellano

The invention relates to 17&#x3b1;-(5-hydroxy-C-hydrocarbyl)-1,3,5(10)-estratrien-3,17&#x3b2;-diol derivatives having cicatrising activity, preferably for topical use on wounds, without significant systemic effects, and to pharmaceutical compositions containing them. In particular, the invention relates to estradiol 17&#x3b1;-(5-hydroxypentyn-1-yl)derivatives and 3-esters, 5'-esters and 3,5&#x2032;-diesters thereof and to a process for the preparation thereof by reaction of 3-OR-protected estrone with an alkali metal derivative of OR-protected 5-pentynol, followed by 3-, 5-&#x2032; or 3,5&#x2032;-esterif&#xca;cation.

17-alpha-substituted derivatives of estradiol with wound-healing activity

A compound having general formula (I) wherein R,, R,, R&prime;,, R,, and R,have the meanings stated in the description, acid addition salts thereof with pharmaceutically acceptable organic and inorganic acids an pharmaceutically acceptable quaternary salts thereof.

Indazole amide compounds as serotoninergic agents

Use of p-aminophenol derivatives for the preparation of pharmaceutical

Phenylcarbamate derivatives suitable to the use as anticholinesterase

Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase activity inhibitors, having general formula (I) ##STR1## where R stands for an amine selected out of the group consisting of ##STR2## and n, R1, R2, R3, and R4 are as defined in the text.

Process for preparing aminoalkylcarbamic esters of eseroline

Thiadiazole derivatives of general formula (I) ##STR1## wherein R.sub.1 is selected from the class consisting of: C.sub.1 -C.sub.10 linear or branched alkyl, benzyl, optionally substituted at the aromatic ring with one or more groups selected on their turn from the class consisting of : C.sub.1 -C.sub.20 linear or branched alkyl residues , nitro groups, halogen atoms, C.sub.1 -C.sub.20 linear or branched alkoxy, hydroxy and C.sub.2 -C.sub.20 linear or branched acyloxy groups, R.sub.2 is selected from H, C.sub.2 -C.sub.10 alkanoyl, cycloalkanoyl wherein this ring has from 3 to 10 carbon atoms, aroyl, and R.sub.3 is selected from H and C.sub.1 -C.sub.10 alkyl, for the treatment of depressive states and anxiety, a process for their preparation and relative pharmaceutical compositions containing them as the active ingredient.

Thiadiazole derivatives for the treatment of depressive states

There are described 8-(1-aminocycloalkyl)-1,3-dialckylxantaine, their derivatives and their salts with adenosine antagonist activity. A process for the preparation of said compounds and pharmaceutical compositions containing them as antidepressant, nootropic and psychostimolant drugs are also described.

8-(1-aminocycloalkyl)-1,3-dialkylxanthine derivatives, preparation

Phosphatidylinositol analogues, inhibitors of phosphatidylinositol-specific phospholipase C of general formula (I) ##STR1## wherein X and R have the meanings specified in the description, suitable for preparing pharmaceutical compositions for the treatment of tumoral, thrombotic and inflammatory type pathologies.

Phosphatidylinositol analogues, inhibitors of phosphatidylinositol

Physostigmine derivatives with acetylcholinesterase inhibition properties, of general formula: ##STR1## in which R is a linear alkyl of from 2 to 20 C. atoms, a branched alkyl, a cycloalkyl or an aryl, when R' is H, or R and R' are linear alkyl of from 2 to 20 C. atoms.

Physostigmine derivatives with acetylcholinesterase inhibition

Aminoalkylcarbamic esters of eseroline suitable for use as

Compounds related to acetazolamide and to its N-methyl derivatives, of the formula: ##STR1## wherein Y is one of the following groups: ##STR2## R.sub.1 being a straight or branched alkylene or arylalkylene, or a phenylene, and the processes for their preparation; the compounds so obtained are inhibitors of carbonic anhydrase like acetazolamide but, in addition, they are well absorbed topically so that they can be used as drugs for treating glaucoma.

Acetazolamide-related compounds, process for their preparation, and

Phosphatidylinositol of high purity useful for the treatment of central nervous system disorders, prepared from vegetal substances containing it by treating them with reagents suitable for the functionalization of the inositol hydroxy group with protective groups, separating the thus protected phosphatidylinositol by solvent extraction or chromatography, and finally removing said protective groups under conditions which do not modify the phosphatidyl group.

Highly pure phosphatidylinositol of natural source useful for the

The herein-described invention concerns new 2,3-dihydro-5-oxy-4,6,7-trimethylbenzofuranes 2-(RS)-substituted, the synthesis procedure and the relative therapeutic use as antioxidizing and radical-scavenging pharmaceuticals with mucoregulation and anti-ischemic properties.

2,3-dihydro-5-oxy-4,6,7-trimethylbenzofurans 2-(RS)-substituted, useful

The present invention relates to (RS)-2-(2,3-dihydro-5-hydroxy-4-,6-trimethylbenozfuranyl) acetic acids and 2-(2,3-dihydro-5-acyloxy-4-,6,7-trimethylbenzofuranyl) acetic acids and esters thereof, the process for producing them and their relevant therapeutical use as mucoregulators and antio-ischemic agents.

Production of (RS)-2-(2,3-dihydro-5-hydroxy-4,6,7-trimethylbenzofuranyl)

Compounds related to acetazolamide and to its N-methyl derivatives, of the formulae: ##STR1## wherein Y is one of the following groups: ##STR2## R.sub.1 being a straight or branched alkylene or arylalkylene, or a phenylene, and the processes for their preparation; the compounds so obtained are inhibitors of carbonic anhydrase like acetazolamide but, in addition, they are well absorbed topically so that they can be used as drugs for treating glaucoma.

Growing community of inventors

Castel Gandolfo, Italy

Mario Brufani